1. p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models.
- Author
-
Grow EJ, Weaver BD, Smith CM, Guo J, Stein P, Shadle SC, Hendrickson PG, Johnson NE, Butterfield RJ, Menafra R, Kloet SL, van der Maarel SM, Williams CJ, and Cairns BR
- Subjects
- Animals, Cell Differentiation genetics, Cellular Reprogramming, DNA Damage, Gene Expression Regulation, Developmental, Homeodomain Proteins metabolism, Humans, Mice, Mice, Knockout, Mouse Embryonic Stem Cells cytology, Muscular Dystrophy, Facioscapulohumeral genetics, Nuclear Proteins genetics, Pluripotent Stem Cells physiology, Transcription Factors genetics, Tumor Suppressor Protein p53 metabolism, Zygote cytology, Homeodomain Proteins genetics, Mouse Embryonic Stem Cells physiology, Muscular Dystrophy, Facioscapulohumeral pathology, Tumor Suppressor Protein p53 genetics
- Abstract
In mammalian embryos, proper zygotic genome activation (ZGA) underlies totipotent development. Double homeobox (DUX)-family factors participate in ZGA, and mouse Dux is required for forming cultured two-cell (2C)-like cells. Remarkably, in mouse embryonic stem cells, Dux is activated by the tumor suppressor p53, and Dux expression promotes differentiation into expanded-fate cell types. Long-read sequencing and assembly of the mouse Dux locus reveals its complex chromatin regulation including putative positive and negative feedback loops. We show that the p53-DUX/DUX4 regulatory axis is conserved in humans. Furthermore, we demonstrate that cells derived from patients with facioscapulohumeral muscular dystrophy (FSHD) activate human DUX4 during p53 signaling via a p53-binding site in a primate-specific subtelomeric long terminal repeat (LTR)10C element. In summary, our work shows that p53 activation convergently evolved to couple p53 to Dux/DUX4 activation in embryonic stem cells, embryos and cells from patients with FSHD, potentially uniting the developmental and disease regulation of DUX-family factors and identifying evidence-based therapeutic opportunities for FSHD., (© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2021
- Full Text
- View/download PDF